Chattem explores homeopathy
This article was originally published in The Tan Sheet
Executive Summary
Firm "is working to develop alternate formulations for Sportscreme and Aspercreme" in case FDA does not look favorably on available clinical data for active ingredient trolamine salicylate, Chattem says in recent 10-K filing. Firm also states it could market the pain relief products as homeopathic agents, or submit new studies on ingredient's safety and efficacy. In May 2001, FDA recommended Chattem adjust the protocol for a proposed study to more accurately reflect the actual use of topical analgesics (1"The Tan Sheet" May 7, 2001, p. 4)...
You may also be interested in...
Chattem Trolamine Salicylate Arthritis, Muscle Pain Studies Urged By FDA
Chattem should consider allowing study subjects to apply 10% trolamine salicylate cream to any painful joints or muscles, although efficacy studies could focus only on a single joint or muscle, FDA Division of OTC Drug Products Director Charles Ganley, MD, said at a May 1 feedback meeting.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.